A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Inclusion Criteria

• •Age 18 through 80 years
• •Written consent
• •Diagnosis of adult onset Rheumatoid Arthritis (RA) as defined by the 2010 American College of Rheumatology European League Against Rheumatism (ACR/EULAR) classification criteria
• •Moderately active disease as defined by disease activity score in 28 joints C-reactive protein (DAS28\[CRP\]) greater than or equal to (\>=) 3.2 at screening and DAS28 erythrocyte sedimentation rate(ESR) ≥ 3.2 at Day 1
• •Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)
• •At least 4 swollen joints
• •Inadequate response to one or two anti-TNF agents other than the study comparator, as defined by the protocol
• •Receiving oral or injectable methotrexate, as defined by the protocol.